Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023:190:143-179.
doi: 10.1007/978-3-031-45654-1_5.

Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer

Wei Liang Gan  1 , Larry Ng  1 , Bryan Y L Ng  1 , Leilei Chen  2   3   4
Affiliations
Review

Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer

Wei Liang Gan et al. Cancer Treat Res. 2023.

Abstract

RNA epigenetics, or epitranscriptome, is a growing group of RNA modifications historically classified into two categories: RNA editing and RNA modification. RNA editing is usually understood as post-transcriptional RNA processing (except capping, splicing and polyadenylation) that changes the RNA nucleotide sequence encoded by the genome. This processing can be achieved through the insertion or deletion of nucleotides or deamination of nucleobases, generating either standard nucleotides such as uridine (U) or the rare nucleotide inosine (I). Adenosine-to-inosine (A-to-I) RNA editing is the most prevalent type of RNA modification in mammals and is catalyzed by adenosine deaminase acting on the RNA (ADAR) family of enzymes that recognize double-stranded RNAs (dsRNAs). Inosine mimics guanosine (G) in base pairing with cytidine (C), thereby A-to-I RNA editing alters dsRNA secondary structure. Inosine is also recognized as guanosine by the splicing and translation machineries, resulting in mRNA alternative splicing and protein recoding. Therefore, A-to-I RNA editing is an important mechanism that causes and regulates "RNA mutations" in both normal physiology and diseases including cancer. In this chapter, we reviewed current paradigms and developments in the field of A-to-I RNA editing in the context of cancer.

Keywords: Adenosine deaminases acting on RNA (ADARs); Adenosine-to-inosine (A-to-I) RNA editing; Cancer; Editing regulator; Immunogenic RNA; Innate immunity; RNA sensing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Aktas T, Avsar Ilik I, Maticzka D, Bhardwaj V, Pessoa Rodrigues C, Mittler G, Manke T, Backofen R, Akhtar A (2017) DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature 544:115–119 - PubMed - DOI
    1. Anadon C, Guil S, Simo-Riudalbas L, Moutinho C, Setien F, Martinez-Cardus A, Moran S, Villanueva A, Calaf M, Vidal A et al (2016) Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 35:4407–4413 - PubMed - DOI
    1. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S (2014) CircRNA biogenesis competes with pre-mRNA splicing. Mol Cell 56:55–66 - PubMed - DOI
    1. Athanasiadis A, Rich A, Maas S (2004) Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol 2:e391 - PubMed - PMC - DOI
    1. Bajad P, Ebner F, Amman F, Szabo B, Kapoor U, Manjali G, Hildebrandt A, Janisiw MP, Jantsch MF (2020) An internal deletion of ADAR rescued by MAVS deficiency leads to a minute phenotype. Nucleic Acids Res 48:3286–3303 - PubMed - PMC - DOI

LinkOut - more resources